1. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakker AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775
2. Kakkar AK, Brenner B, Dahl OE, Erikson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hiparthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:29-37
3. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786
4. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673–1680
5. Kakkar AK, et al. SICOT 2008; A18755
6. Eriksson BI, et al. J Bone Joint Surg Br. 2009;91-B:636–644
7. Xarelto® Summary of Product Characteristics, Bayer Schering Pharma AG
1. Eriksson BI, Kakkar AK, Turpie AGG, Lassen MR, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surgery. 2009;91-B:636-644.
2. Turpie AGG, Lassen MR, Kakkar AK, et al. A pooled analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: effect on symptomatic venous thromboembolism, all-cause mortality and bleeding. Poster presented at: the European Society of Cardiology (ESC); August 30-September 3, 2008; Munich, Germany. Abstract 86450.
3. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
4. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.
5. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
6. Turpie AGG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680.
7. www.clinicaltrials.gov
